Search This Blog

Monday, May 10, 2021

GAVI in talks with China's Sinopharm, other vaccine makers for COVAX doses

 The GAVI Vaccine Alliance is in talks with COVID-19 vaccine manufacturers including China's state-owned Sinopharm to expand the COVAX pipeline and secure doses for distribution, a GAVI spokeswoman said on Monday.

Sinopharm received emergency use listing from the World Health Organization (WHO) last Friday, making it eligible for the COVAX program and bolstering Beijing's push for a bigger role in inoculating the world.

COVAX, run jointly by GAVI and the WHO to provide doses to the world's poorest people, has hit major supply problems. To date the AstraZeneca shot made by the Serum Institute of India account for most doses rolled out, but authorities there have restricted exports because of India's massive epidemic.

"GAVI, on behalf of the COVAX Facility, is in dialog with several manufacturers, including Sinopharm, to expand and diversify the portfolio further and secure access to additional doses for Facility participants," a spokeswoman told Reuters on Monday in response to a query.

"Following on from the new announcements on Moderna and Novavax, we will continue to provide updates on any new deals in due course," she added, referring to the U.S. vaccine makers.

Novavax Inc said on Thursday it has agreed with GAVI to manufacture and distribute 350 million doses of its COVID-19 vaccine to countries participating under COVAX.

Moderna will supply 34 million doses of its COVID-19 vaccine this year to the COVAX program, with 466 million available next year, Gavi said last week.

GAVI, appealing for full financing of COVAX, said on Monday that it would require an additional $1.7 billion at the least by June to lock in supplies for 2021 and early 2022.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/GAVI-in-talks-with-China-s-Sinopharm-other-vaccine-makers-for-COVAX-doses-33208466/

China healthcare firms surge after vaccine waiver plan meets EU resistance

 

Shares of Chinese healthcare firms soared on Monday, rebounding from last week's drubbing after a U.S. proposal to waive patents for COVID-19 vaccines met with fierce opposition from European governments and pharmaceutical giants.

A sub-index tracking health care firms was 1.83% higher at midday, after falling more than 6.8% last week, its worst weekly performance in 10 weeks. That compared with a 0.15% loss for the blue-chip CSI300 index on Monday.

The health care sector received a further boost after Shanghai Fosun Pharmaceutical said on Sunday that a subsidiary has agreed to provide a factory to make up to 1 billion doses annually of the COVID-19 vaccine developed by BioNTech in China.

On Monday, Fosun Pharmacetical's Shanghai shares soared by the 10% daily limit. Its Hong Kong shares jumped as much as 22.58% higher and were last up 17.78%.

Shanghai shares of CanSino Biologics Inc gained 9.344% and its Hong Kong shares jumped 5.14%

U.S. President Joe Biden backed a proposal last week to waive patent rights on coronavirus vaccines, but his support was rebuffed by European leaders who questioned the usefulness of a waiver and argued that making and sharing vaccines more quickly should take priority.

The European Union, however, is ready to discuss a concrete proposal around vaccine waivers despite scepticism, the chairman of EU leaders said on Saturday.

The jump in Chinese vaccine shares also came as analysts downplayed the threat posed by patent waivers.

"The main vaccine threshold is actually more on the production side, and patent liberalisation will not necessarily lead to a large number of mRNA vaccines being copied by companies," said Wang Ruizhe, an analyst at Capital Securities.

Pfizer-BioNTech and Moderna vaccines use new mRNA technology involving the injection of a small part of the virus's genetic code (RNA) to stimulate the recipient's immune response.

Wang said that a strong reaction from U.S. pharmaceutical companies to the waiver proposal meant there were still "variables" around relaxations of vaccine intellectual property.

https://www.marketscreener.com/quote/stock/CHINA-HEALTH-GROUP-LIMITE-6170590/news/China-healthcare-firms-surge-after-vaccine-waiver-plan-meets-EU-resistance-33206511/

Cantor Fitzgerald Downgrades Ocugen to Neutral

 

From Overweight, Adjusts PT to $11 From $15


https://www.marketscreener.com/quote/stock/OCUGEN-INC-19157135/news/Ocugen-nbsp-Cantor-Fitzgerald-Downgrades-Ocugen-to-Neutral-From-Overweight-Adjusts-PT-to-11-From-33197468/

BioNTech Q1 results, corporate update

 

  • More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021

  • Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyond

  • Announced planned expansion of global footprint to Asia with establishment of first regional headquarters for south east Asia in Singapore, including a fully-integrated and state-of-the art mRNA manufacturing facility

  • In oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials

Conference call and webcast scheduled for May 10, 2021, at 8:00 a.m. ET (2:00 p.m. CET)

Update on current signed COVID-19 vaccine order book:

Estimated COVID-19 vaccine revenues to BioNTech upon delivery of currently signed supply contracts of ~1.8 billion doses is ~€12.4 billion.



This revenue estimate reflects:





Additional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond.



Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.

On Track with Previously Stated 2021 Financial Outlook

https://finance.yahoo.com/news/biontech-announces-first-quarter-2021-110000704.html

BioNTech to build mRNA vaccine manufacturing site in Singapore

 BioNTech plans to set up a regional centre and a new factory in Singapore for its vaccines, it said on Monday, boosting its presence in Asia as a debate over patents rages and pressure grows on drugmakers to raise output of COVID-19 shots.

Governments are looking to build up local vaccine production to secure access to supplies after manufacturing setbacks have slowed the rollout of COVID-19 doses in some countries.

The Singapore facility will "address potential pandemic threats" in southeast Asia and will increase BioNTech's global supply capacity of product candidates - also beyond vaccines - based on messenger RNA (mRNA) technology, BionTech said.

MRNA vaccines, like BionTech and Pfizer's COVID-19 shot, prompt the human body to make a protein that is part of the virus, triggering an immune response.

The German biotech company said the Singapore factory will have an estimated annual capacity of several hundred million doses of its mRNA vaccines depending on the specific type, once it is operational in 2023.

"Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities," said Ugur Sahin, CEO and Co-founder of BioNTech.

CHINA VENTURE

Leading vaccine makers have come under growing pressure to free up their COVID-19 vaccine patents to aid poor countries. BioNTech and other vaccine makers have said they were already transferring vital production knowledge to other parts of the world.

BioNTech and Pfizer are jointly commercializing the vaccine worldwide, excluding China, Macau, Hong Kong and Taiwan, which are covered by BioNTech’s collaboration with Fosun Pharma.

BioNTech and Fosun Pharma have done clinical trials in China but Fosun had not started producing the vaccine, which has yet to be granted approval there.

Fosun said on Sunday it would provide a factory with an annual capacity to make up to 1 billion doses of the COVID-19 vaccine under a joint venture with BioNTech.

This marks a step closer for China to have localized manufacturing capability for the German firm's vaccine. Five domestically-developed COVID-19 vaccines are being used in the country, while no foreign ones have gained regulatory approval.

BioNTech plans to open the Singapore office in 2021 and expects the manufacturing site to be operational by 2023, creating up to 80 jobs in Singapore.

The establishment of a southeast Asia regional hub, which is supported by the Singapore Economic Development Board, comes after BioNTech, based in Mainz, Germany, set up a U.S. headquarters in Cambridge, Massachusetts in 2020.

BioNTech has said it and Pfizer would have capacity to produce up to 3 billion doses in 2021. Pfizer said last week the pair was targeting production of 4 billion doses next year, mostly for low- and middle-income countries.

https://finance.yahoo.com/news/1-biontech-build-mrna-manufacturing-062246669.html

Checkmate, Regeneron to Evaluate Combo for Skin Cancer

  Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the development program expansion of vidutolimod (CMP-001) into non-melanoma skin cancers in combination with Libtayo® (cemiplimab) under a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”). Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Cemiplimab is a PD-1 blocking antibody being jointly developed by Regeneron and Sanofi.

Checkmate and Regeneron will collaborate on a multi-indication, Phase 2, proof-of-concept clinical trial of vidutolimod in combination with cemiplimab in the following patient cohorts: (a) PD-1 treatment-naïve subjects with cutaneous squamous cell carcinoma (CSCC), (b) subjects with cutaneous squamous cell carcinoma (CSCC) that is refractory to PD-1 blockade, and (c) subjects with Merkel cell carcinoma (MCC) that is refractory to PD-1 blockade. Checkmate will be the sponsor of the clinical trial, and Regeneron will supply cemiplimab.

https://finance.yahoo.com/news/checkmate-pharmaceuticals-announces-clinical-supply-100000207.html

Sunday, May 9, 2021

Critical Race Theory Training In Workplace Could Lead To Increased Bullying, Anxiety

 by Janita Kan via The Epoch Times (emphasis ours),

HR expert and author Jim Stroud says the impact of critical race theory (CRT) in workplace training could be detrimental to employees because it could lead to increased bullying and anxiety in the workplace.

he the quasi-Marxist theory has been heavily promulgated throughout academia, entertainment, government, schools, and the workplace in recent years and rose to new prominence following the rise of far-left groups such as Antifa and Black Lives Matter. Some workplaces have included concepts from the doctrine in their “racial and cultural sensitivity” training, which essentially teaches employees that the United States is fundamentally racist, or that one race is inherently superior to another race.

Stroud, who has 20 years’ experience in human resources and has written about CRT’s impact on the workplace, argues that such training could negatively impact workplace dynamics and teaches employees to mistrust each other.

“So imagine that you’re working in a space and the day before the training, everything was fine,” Stroud told NTD’s “The Nation Speaks.” “You work with your co-workers, you had good friendships, good team building exercises, everything is fine. After the training, you’re looking at your co-workers in a different way. You’re wondering, okay, I thought you were my friend but because of this training, I now believe that you’re oppressing me, so I don’t really know if we’re really friends. I don’t really know if we’re really working together. I don’t know if the reason why you refused me taking on some project is because my idea wasn’t valid or because you’re racist.”

Employees may also question whether they were chosen to work on a certain project because they were suitable for the job or because of some corporate policy aiming to fulfill at curbing discrimination stemming from intersectionality, he added. Intersectionality is the concept where different aspects of a person’s identity can expose them to overlapping forms of discrimination and marginalization.

“So I also think that it would bring about a lot of anxiety inside the workplace because if people disagree with critical race theory then you will be accused of being racist, which is what critical race theory does,” he said.

If an employee continues to deny that accusation, the CRT states that that individual is “all the more racist,” he explained. Eventually, this anxiety in some people could lead to hostile workplaces.

Stroud said that CRT is essentially a “movement to make racism acceptable,” saying it teaches the idea that “white people are born oppressors without redemption and that all minorities are oppressed.”

It teaches that the most important thing about anyone is their skin color, not their character, not the things they do, not the personality, not even the environment that they inhabit,” he said. “That’s purely telling you that your worth and everything you are is measured in the color of your skin.”

The movement to push back on the expansion of CRT in schools and workplace training has fueled a heated debate on how cultural and racial sensitivity education should be conducted. Conservatives and Republicans have warned that the CRT movement is not about eliminating racism, and is simply pushing divisive concepts. Meanwhile, progressives and Democrats argue that the CRT approach would advance equity for all.

During his administration, President Donald Trump placed a ban on critical race theory training in federal workplaces, but President Joe Biden rescinded the measure. Instead, Biden has promoted policies that embrace the ideology, issuing an executive order stating that the federal government must pursue “a comprehensive approach to advancing equity for all.”

Stroud said he believes that the best way for corporations who are grappling with partisan politics in their organization is to attempt to steer conversations away from politics, but he warned that this could prompt backlash, citing the example of employee exodus at software firm Basecamp. The technology company saw mass resignations after its CEO announced that its employees are banned from openly sharing their “societal and political discussions” at work.

In a blog post, Basecamp CEO Jason Fried explained that the discussions are “a major distraction,” “saps our energy,” and “redirects our dialog toward dark places.”

It’s not healthy, it hasn’t served us well. And we’re done with it on our company Basecamp account where the work happens. People can take the conversations with willing co-workers to Signal, Whatsapp, or even a personal Basecamp account, but it can’t happen where the work happens anymore,” he said.

Stroud said he also hopes to see legislative measures that would make an individual’s political affiliation a protected class under state or federal discrimination laws in order to counter discrimination or bullying based on a person’s political beliefs.

“Hopefully by the time of the election, it’ll become law. I think will be tricky because talking about politics is is something that both sides need,” he said, adding that given the Democrat-controlled Congress, it is unlikely that such a law would pass.

https://www.zerohedge.com/political/critical-race-theory-training-workplace-could-lead-increased-bullying-anxiety-expert-says